Oncology Clinical Trials Market Size, Share, Trends, & Industry Analysis Report By Cancer Type (Lung cancer, Breast cancer, Thyroid cancer), By Phase, By Study Design, and By Region – Market Forecast, 2025–2034

The oncology clinical trials market size is expected to reach USD 23.50 Billion by 2034, according to a new study by Polaris Market Research. The report “Oncology Clinical Trials Market Share, Size, Trends, Industry Analysis Report: By Cancer Type (Lung cancer, Breast cancer, Thyroid cancer), By Phase, By Study Design, and By Region; Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The oncology clinical trials market provides integrated solutions for pharmaceutical, biotechnology and research sectors. The market includes clinical trials across cancer types, phases, and study designs supporting drug development, drug delivery, regulatory approvals, and patient access to innovative therapies.

Market growth is driven by rising global cancer prevalence, increasing investment in oncology drug development, and advancements in targeted and immunotherapy treatments.

Oncology Clinical Trials Market Report Highlights

Based on cancer type, the lung cancer segment dominated in 2024, driven by high prevalence and strong adoption of targeted and immunotherapy trials.

In terms of phase, the phase I segment dominated in 2024, fueled by early-stage safety and dosage studies for new oncology therapies.

Based on study design, the interventional segment dominated in 2024 due to high adoption of experimental and controlled trials for novel therapies.

North America dominated the global market in 2024, supported by advanced clinical research infrastructure and high cancer incidence.

Asia Pacific is projected to record the fastest growth, driven by rising cancer prevalence and expanding healthcare access in emerging markets.

Key players in the global market include Pfizer Inc., Novartis AG, F. Hoffmann-La Roche AG, Bristol-Myers Squibb Company, Merck & Co., Inc., Johnson & Johnson, AstraZeneca plc, Eli Lilly and Company, Amgen Inc., AbbVie Inc., Gilead Sciences, Inc., and Takeda Pharmaceutical Company Ltd.

Polaris Market Research has segmented the market report based on cancer type, phase, study design, and region:

By Cancer Type (Revenue, USD Billion, 2020–2034)

Lung cancer

Breast cancer

Thyroid cancer

Leukemia

Liver cancer

Skin cancer

Lymphoma

Pancreatic cancer

Prostate cancer

Colon & rectal cancer

Urinary system cancer

Other cancer

By Phase (Revenue, USD Billion, 2020–2034)

Phase I

Phase II

Phase III

Phase IV

By Study Design (Revenue, USD Billion, 2020–2034)

Interventional

Observational

Expanded Access

By Regional Outlook (Revenue, USD Billion, 2020–2034)

North America

US

Canada

Europe

Germany

France

UK

Italy

Spain

Netherlands

Russia

Rest of Europe

Asia Pacific

China

Japan

India

Malaysia

South Korea

Indonesia

Australia

Vietnam

Rest of Asia Pacific

Middle East & Africa

Saudi Arabia

UAE

Israel

South Africa

Rest of Middle East & Africa

Latin America

Mexico

Brazil

Argentina

Rest of Latin America Show more